27.03.2014 • NewsDede WillamsDuPontInvista

Invista Breaks Ground for HMD and PA 6.6 Plants in China

U.S. polyamide producer Invista has broken ground for a new 215,000 t/y hexamethylene diamine (HMD) plant and a 150,000 t/y PA 6.6 polymerization plant in China's Shanghai Chemical Industry Park (SCIP).

Both units are scheduled to start up in 2015.

The privately owned Kansas City, Missouri-based company that bought the DuPont business and secured the nylon brand name in 2004 said the new facilities mark a key milestone in its plans for integrated PA 6.6 production in China and underscore its commitment to the region.

Along with the HMD and polymer plants, Invista also plans to build a 300,000-t/y adiponitrile (ADN) plant at SCIP, which it claims will be among the most energy-efficient nylon intermediates sites in the world. Overall investment will exceed $1 billion - the company's largest capital investments to date.

"China is one of the most important regions for our growth strategy," said Invista CEO Jeff Gentry. "We have seen significant growth in the region in recent years, and we plan to continue to bring our latest innovative technologies here."

Warren Primeaux, president of Invista Intermediates, said the company believes that China is driving global nylon demand growth, and the use of nylon 6.6 intermediates and polymer in the region will increase. "The new facilities will enable Invista to provide customers with better service, shorter lead time and a local resource for production," he said.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.